Skip to main content
Veterinary Medicines

Vectormune FP ILT + AE (--) Lyophilisate and solvent for suspension for injection

Authorised
  • Fowlpox virus, strain rFP-LT, expressing fusion protein gene and encapsidation protein gene of Infectious laryngotracheitis virus, Live
  • Avian encephalomyelitis virus, strain Calnek 1143, Live

Product identification

Medicine name:
Vectormune FP ILT + AE (--) Lyophilisate and solvent for suspension for injection
Active substance:
  • Fowlpox virus, strain rFP-LT, expressing fusion protein gene and encapsidation protein gene of Infectious laryngotracheitis virus, Live
  • Avian encephalomyelitis virus, strain Calnek 1143, Live
Target species:
  • Chicken
Route of administration:
  • Wing-web-stab use

Product details

Active substance and strength:
  • Fowlpox virus, strain rFP-LT, expressing fusion protein gene and encapsidation protein gene of Infectious laryngotracheitis virus, Live
    Presentation_strength:2.7 to 4.5 log₁₀ TCID₅₀ Reference:HSE Index:0
  • Avian encephalomyelitis virus, strain Calnek 1143, Live
    Presentation_strength:2.7 to 4.5 log₁₀ EID₅₀ Reference:HSE Index:1
Pharmaceutical form:
  • Lyophilisate and solvent for suspension for injection
Withdrawal period by route of administration:
  • Wing-web-stab use
    • Chicken
      • Not applicable
        0
        day
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI01AD
Authorisation status:
  • Valid
Authorised in:
  • Austria
  • Belgium
  • Bulgaria
  • Croatia
  • Cyprus
  • Czechia
  • Denmark
  • Estonia
  • Finland
  • France
  • Germany
  • Greece
  • Hungary
  • Iceland
  • Ireland
  • Italy
  • Latvia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Malta
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Romania
  • Slovakia
  • Slovenia
  • Spain
  • Sweden
  • United Kingdom (Northern Ireland)
Package description:
  • Packaging:Lyophilisate: vial (glass); solvent: vial (glass), Package_size:Lyophilisate: 1 vial; solvent: 1 vial; 1 pronged applicator, Content:Lyophilisate: 2000 doses; solvent: 20 ml
  • Packaging:Lyophilisate: vial (glass); solvent: vial (glass), Package_size:Lyophilisate: 10 vials; solvent: 10 vials; 10 pronged applicators, Content:Lyophilisate: 2000 doses; solvent: 20 ml
  • Packaging:Lyophilisate: vial (glass); solvent: vial (glass), Package_size:Lyophilisate: 10 vials; solvent: 10 vials; 10 pronged applicators, Content:Lyophilisate: 1000 doses; solvent: 10 ml
  • Packaging:Lyophilisate: vial (glass); solvent: vial (glass), Package_size:Lyophilisate: 5 vials; solvent: 5 vials; 5 pronged applicators, Content:Lyophilisate: 1000 doses; solvent: 10 ml
  • Packaging:Lyophilisate: vial (glass); solvent: vial (glass), Package_size:Lyophilisate: 1 vial; solvent: 1 vial; 1 pronged applicator, Content:Lyophilisate: 1000 doses; solvent: 10 ml
  • Packaging:Lyophilisate: vial (glass); solvent: vial (glass), Package_size:Lyophilisate: 5 vials; solvent: 5 vials; 5 pronged applicators, Content:Lyophilisate: 2000 doses; solvent: 20 ml

Additional information

Entitlement type:
  • Marketing Authorisation
Marketing authorisation holder:
  • Ceva-Phylaxia Co. Ltd
Marketing authorisation date:
Manufacturing sites for batch release:
  • Ceva-Phylaxia Veterinary Biologicals Co. Ltd
Responsible authority:
  • European Commission
Authorisation number:
This information is not available for this product.
Date of authorisation status change:

Documents

Combined File of all Documents

English (PDF)
Published on: 9/04/2024
Download
Bulgarian (PDF)
Published on: 9/04/2024
Croatian (PDF)
Published on: 9/04/2024
Czech (PDF)
Published on: 9/04/2024
Danish (PDF)
Published on: 9/04/2024
Dutch (PDF)
Published on: 9/04/2024
Estonian (PDF)
Published on: 9/04/2024
Finnish (PDF)
Published on: 9/04/2024
French (PDF)
Published on: 9/04/2024
German (PDF)
Published on: 9/04/2024
Greek (PDF)
Published on: 9/04/2024
Hungarian (PDF)
Published on: 9/04/2024
Icelandic (PDF)
Published on: 9/04/2024
Italian (PDF)
Published on: 9/04/2024
Latvian (PDF)
Published on: 9/04/2024
Lithuanian (PDF)
Published on: 9/04/2024
Maltese (PDF)
Published on: 9/04/2024
Norwegian (PDF)
Published on: 9/04/2024
Polish (PDF)
Published on: 9/04/2024
Portuguese (PDF)
Published on: 9/04/2024
Romanian (PDF)
Published on: 9/04/2024
Slovak (PDF)
Published on: 9/04/2024
Slovenian (PDF)
Published on: 9/04/2024
Spanish (PDF)
Published on: 9/04/2024
Swedish (PDF)
Published on: 9/04/2024
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."